Literature DB >> 1691831

Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone.

G B De Sarro1, Y Masuda, C Ascioti, M G Audino, G Nistico.   

Abstract

Rat interferon, alpha-interferon, interleukin 2 and recombinant interleukin-2 injected into the third cerebral ventricle produced typical behavioural sedation and/or sleep and ECoG synchronization in rats while beta-interferon produced no behavioural sleep or ECoG synchronization. A slight sedation was observed after the largest dose of beta-interferon only. During sleep induced by lymphokines, a dose-dependent increase in total voltage power as well as in the 0.5-3, 4-7 and 12-16 Hz frequent bands was observed. Much smaller doses were required to produce similar behavioural and ECoG spectrum effects after infusion of interferons and interleukin-2 into the locus coeruleus. No significant behavioural and ECoG changes were obtained after infusion of the same doses of interferons and interleukin-2 into other areas of the brain (caudate nucleus, dorsal hippocampus, substantia nigra pars compacta, ventromedial hypothalamus). The behavioural and ECoG effects of alpha-interferon, rat interferon and interleukin-2 were blocked in animals pretreated with naloxone. These results are consistent with the hypothesis that the behavioural and ECoG effects of these lymphokines are mediated at locus coeruleus level by stimulation of opiate receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691831     DOI: 10.1016/0028-3908(90)90057-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

1.  A cytokine study in children and adolescents with Tourette's disorder.

Authors:  Vilma Gabbay; Barbara J Coffey; Leah E Guttman; Lev Gottlieb; Yisrael Katz; James S Babb; Mia M Hamamoto; Charles J Gonzalez
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-05-07       Impact factor: 5.067

Review 2.  Cytokines in immune function and sleep regulation.

Authors:  James M Krueger; Jeannine A Majde; David M Rector
Journal:  Handb Clin Neurol       Date:  2011

3.  Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test.

Authors:  M Makino; Y Kitano; C Komiyama; M Hirohashi; K Takasuna
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 4.  Central nervous system and peripheral immune functions and the sleep-wake system.

Authors:  H Moldofsky
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

Review 5.  Sleep Disturbance and Alzheimer's Disease: The Glial Connection.

Authors:  Aditya Sunkaria; Supriya Bhardwaj
Journal:  Neurochem Res       Date:  2022-03-18       Impact factor: 3.996

6.  Spinal injection of IL-2 or IL-15 alters mechanical and thermal withdrawal thresholds in rats.

Authors:  Juan P Cata; Han-Rong Weng; Patrick M Dougherty
Journal:  Neurosci Lett       Date:  2008-03-29       Impact factor: 3.046

7.  Inhibition by interleukin-1 beta of noradrenaline release in rat spleen: involvement of lymphocytes, NO and opioid receptors.

Authors:  I T Bognar; S A Albrecht; M Farasaty; H Fuder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

8.  Probable neuroimmunological link between Toxoplasma and cytomegalovirus infections and personality changes in the human host.

Authors:  Martina Novotná; Jitka Hanusova; Jirí Klose; Marek Preiss; Jan Havlicek; Katerina Roubalová; Jaroslav Flegr
Journal:  BMC Infect Dis       Date:  2005-07-06       Impact factor: 3.090

Review 9.  Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression.

Authors:  Cristy Phillips; Atoossa Fahimi
Journal:  Front Neurosci       Date:  2018-07-26       Impact factor: 4.677

Review 10.  Neurogenic switching: a hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity.

Authors:  W J Meggs
Journal:  Environ Health Perspect       Date:  1995-01       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.